The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Open accessAbstract
BACKGROUND: Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS: Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium levels of 5.1 to less than 6.5 mmol per liter received patiromer (at an initial dose of 4.2 g or 8.4 g twice a day) for 4 weeks (initial treatment phase); the primary efficacy end point was the mean change in the serum potassium level from baseline to week 4. Eligible patients at the end of week 4 (those with a baseline potassium level of 5.5 to <6.5 mmol per liter in whom the level decreased to 3.8 to <5.1 mmol per liter) entered an 8-week randomized withdrawal phase in which they were randomly assigned to continue patiromer or switch to placebo; the primary efficacy end point was the between-group difference in the median change in the serum potassium level over the first 4 weeks of that phase. RESULTS: In the initial treatment phase, among 237 patients receiving patiromer who had at least one potassium measurement at a scheduled visit after day 3, the mean (±SE) change in the serum potassium level was -1.01±0.03 mmol per liter (P<0.001). At week 4, 76% (95% confidence interval, 70 to 81) of the patients had reached the target potassium level (3.8 to <5.1 mmol per liter). Subsequently, 107 patients were randomly assigned to patiromer (55 patients) or placebo (52 patients) for the randomized withdrawal phase. The median increase in the potassium level from baseline of that phase was greater with placebo than with patiromer (P<0.001); a recurrence of hyperkalemia (potassium level, ≥5.5 mmol per liter) occurred in 60% of the patients in the placebo group as compared with 15% in the patiromer group through week 8 (P<0.001). Mild-to-moderate constipation was the most common adverse event (in 11% of the patients); hypokalemia occurred in 3%. CONCLUSIONS: In patients with chronic kidney disease who were receiving RAAS inhibitors and who had hyperkalemia, patiromer treatment was associated with a decrease in serum potassium levels and, as compared with placebo, a reduction in the recurrence of hyperkalemia. (Funded by Relypsa; OPAL-HK ClinicalTrials.gov number, NCT01810939.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
(2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.003 · Cited by 1,245
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 646
Self-citationManaging hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Rank Methods for Combination of Independent Experiments in Analysis of Variance
Hodges, J. L., & Lehmann, E. L. (1962) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177704575 · Cited by 396
Rank Methods for Combination of Independent Experiments in Analysis of Variance
Hodges, J. L., & Lehmann, E. L. (2012) · Selected Works of E. L. Lehmann · doi:10.1007/978-1-4614-1412-4_35 · Cited by 373
Harel, Z., Harel, S., Shah, P. S., Wald, R., Perl, J., & Bell, C. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.016 · Cited by 322
Ion-Exchange Resins for the Treatment of Hyperkalemia: Are They Safe and Effective?
Sterns, R. H., Rojas, M., Bernstein, P., & Chennupati, S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010079 · Cited by 303
Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Weir, M. R., & Rolfe, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07821109 · Cited by 265
Self-citationUse of Aldosterone Antagonists in Heart Failure
Albert, N. M. (2009) · JAMA · doi:10.1001/jama.2009.1493 · Cited by 262
Rossignol, P., Dobre, D., McMurray, J. J. V., Swedberg, K., Krum, H., van Veldhuisen, D. J., Shi, H., Messig, M., Vincent, J., Girerd, N., et al. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.113.000792 · Cited by 260
Self-citationEschalier, R., McMurray, J. J. V., Swedberg, K., van Veldhuisen, D. J., Krum, H., Pocock, S. J., Shi, H., Vincent, J., Rossignol, P., Zannad, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.086 · Cited by 247
Self-citationReardon, L. C., & Macpherson, D. S. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.26 · Cited by 222
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164 · cited 2×
“A total of 243 patients were enrolled in the initial treatment phase (92 with mild hyperkalemia and 151 with moderate-to-severe hyperkalemia) at sites in Eastern Europe (24 sites), the European Union (21), and the United States (14).”
BackgroundSelf-citationManagement of Hyperkalemia with a Cation-Exchange Resin
Scherr, L., Ogden, D. A., Mead, A. W., Spritz, N., & Rubin, A. L. (1961) · New England Journal of Medicine · doi:10.1056/nejm196101192640303 · Cited by 148
Intestinal Necrosis due to Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol
McGowan, C., Saha, S., Chu, G., Resnick, M. B., & Moss, S. F. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819e8978 · Cited by 135
Yıldırım, T., Arıcı, M., Pişkinpaşa, S., Kutlugün, A. A., Yılmaz, R., Altun, B., Erdem, Y., & Turgan, Ç. (2012) · Renal Failure · doi:10.3109/0886022x.2012.717478 · Cited by 75
The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia
Kessler, C. S., Ng, J., Valdez, K., Xie, H. W., & Geiger, B. L. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.834 · Cited by 67
Buysse, J., Huang, I., & Pitt, B. (2011) · Future Cardiology · doi:10.2217/fca.11.71 · Cited by 60
Self-citationChernin, G., Gal‐Oz, A., Ben–Assa, E., Schwartz, I. F., Weinstein, T., Schwartz, D., & Silverberg, D. S. (2011) · Clinical Cardiology · doi:10.1002/clc.20987 · Cited by 52
Semi-parametric and non-parametric methods for clinical trials with incomplete data
O’Brien, P. C., Zhang, D., & Bailey, K. R. (2004) · Statistics in Medicine · doi:10.1002/sim.1963 · Cited by 32
Eschalier, R., McMurray, J. J. V., Swedberg, K. B., van, D. J. V., Krum, H., Pocock, S., Shi, H., Vincent, J., Rossignol, P., Zannad, F. M., et al. (2014) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2014-10-1-106-115 · Cited by 27
Self-citation
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Self-citation
Metadata
- Authors
- Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J., Christ-Schmidt, H., Berman, L., & Pitt, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-15
- Volume
- 372
- Issue
- 3
- Pages
- 211-221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2324948948
- Cited by
- 669
- References
- 27
- FWCI
- 42.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.